Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University Hospital, Limoges |
---|---|
Information provided by: | University Hospital, Limoges |
ClinicalTrials.gov Identifier: | NCT00551798 |
Predicting response to chemotherapy in patients with Hodgkin's disease or lymphoma high-grade malignant de novo or recurrence.
The non-Hodgkin's lymphoma and high-grade Hodgkin's disease may show resistance to chemotherapy, regardless of their initial extension. The failure of treatment is most often correlated with an incomplete answer or lack of response to chemotherapy as a result chemoresistance. This drug, which may involve the gene MDR1 (multidrug resistance) encoding the protein PGP, can be studied in vivo by MIBI scan. The MIBI is behind a tracer perfusionnel used routinely to explore myocardial perfusion, but it has other characteristics of fixing, which can be used in oncological imaging (fixation by glial tumors of high grade).Prospective Study, which includes conducting a tomoscintigraphie 30 minutes after injection of 20 mCi of 99mTc-MIBI in initial stock or relapse of high-grade lymphoma and Hodgkin's disease any stage (I-IV). Fixing the MIBI is compared with morphological abnormalities detected by CT and the setting of lesions by 18FDG. Patients will be treated in a traditional way, without changes in treatment protocols used in routine. Patients with a negative MIBI scan, will be watched with particular attention in order to detect insufficient response to chemotherapy. The only change, the care of patients, only for the achievement of an initial consideration of non-invasive imaging, further, which is the tomoscintigraphie the MIBI. Of the tumor samples, will be evaluated by immunohistochemistry, the expression of PGP and the MRP1 (two proteins associated with the drug). On blood, may be carried out genotyping of MDR1, MRP1 and MRP2 to the patient.
Condition | Intervention |
---|---|
Hodgkin's Disease Malignant Lymphomas High Grade Chemoresistance |
Procedure: TEP au MIBI |
Study Type: | Interventional |
Study Design: | Diagnostic, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | Prediction of the Response to Chemotherapy by Tomoscintigraphie the MIBI in the Balance Sheet Pre Hodgkin's Disease and Lymphoma Malins High Grade |
Estimated Enrollment: | 90 |
Study Start Date: | March 2005 |
Estimated Study Completion Date: | September 2008 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Jacques MONTEIL, MD | jacques.monteil@unilim.fr |
France | |
Nuclear Medicine | Recruiting |
LIMOGES, France, 87042 | |
Contact: Jacques MONTEIL, MD jacques.monteil@unilim.fr | |
Sub-Investigator: Jean-Claude VANDROUX, MD | |
Sub-Investigator: Sandrine VERBEKE, MD | |
Hematology | Recruiting |
LIMOGES, France, 87042 | |
Contact: Dominique BORDESSOULE, MD 05 55 05 66 42 | |
Sub-Investigator: Arnaud JACCARD, MD | |
Sub-Investigator: Pascal TURLURE, MD | |
Sub-Investigator: Liliane REMENIERAS, MD | |
Sub-Investigator: Stéphane GIRAULT, MD | |
Sub-Investigator: Mohamed TOUATI, MD | |
Sub-Investigator: Stéphane MOREAU, MD | |
Sub-Investigator: Marie-Pierre CHAURY, MD | |
Radiology | Recruiting |
LIMOGES, France, 87042 | |
Contact: Antoine MAUBON, MD 05 55 05 62 60 | |
Sub-Investigator: Michèle DESFOUGERE, MD | |
Anatomo-pathology | Recruiting |
LIMOGES, France, 87042 | |
Contact: Barbara PETIT, MD barbara.petit@chu-limoges.fr | |
Pharmacology | Recruiting |
LIMOGES, France, 87042 | |
Contact: Pierre MARQUET, MD pierre.marquet@unilim.fr |
Principal Investigator: | Jacques MONTEIL, MD | University Hospital, Limoges |
Study ID Numbers: | I04016 |
Study First Received: | October 30, 2007 |
Last Updated: | October 30, 2007 |
ClinicalTrials.gov Identifier: | NCT00551798 |
Health Authority: | French : DGS |
Hodgkin's Disease Malignant lymphomas high grade Chemoresistance MIBI |
PGP MRP1 Tumor response |
Lymphatic Diseases Hodgkin's disease Immunoproliferative Disorders Hodgkin lymphoma, adult |
Lymphoproliferative Disorders Hodgkin Disease Lymphoma |
Neoplasms Neoplasms by Histologic Type Immune System Diseases |